このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

長期薬物療法における禁煙治療の喫煙治療のメタボロミックおよび腸内微生物バイオマーカー:無作為化対照試験

2026年9月28日 更新者:Sigmund Freud PrivatUniversitat

Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.

Objectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.

Methods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.

A cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.

調査の概要

研究の種類

介入

入学 (実際)

97

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Fehring、オーストリア、8350
        • Grüner Kreis Organization Johnsdorf Facility
      • Graz、オーストリア、8036
        • Medical University Graz
      • Vienna、オーストリア、1020
        • Sigmund Freud Private University Vienna

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10
  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness to quit smoking
  • willingness and ability to consent

Inclusion criteria for healthy controls :

  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness and ability to consent

Exclusion Criteria:

  • lack of consent, inability to provide informed consent
  • age below 18,
  • acute psychotic symptoms or acute suicidal tendencies
  • cardiovascular disease
  • pregnancy or breastfeeding
  • severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score <20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)
  • probiotic intake within the last 6 months,
  • ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study
  • prior participation in a smoking cessation programme

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Treatment As Usual

Patients in the TAU group receive long-term rehabilitation drug treatment according to the 'community as a treatment'-model

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

実験的:6-weeks smoking cessation cognitive-behavioral therapy intervention

The "smoke free in 6 weeks" program is a standardized behavioural therapy intervention that takes place once a week for 1.5 hours over 6 weeks and is provided by the Austrian health insurance provider Österreichische Gesundheitskasse (ÖGK).

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.

介入なし:Healthy controls

Control group with n=50 healthy adult subjects, examined at a single timepoint. No interventions will be administered in this arm.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Self-efficacy
時間枠:From enrollment to follow-up 3 months after the end of the 6-weeks treatment period

Self-efficacy as a psychological variable and will be assessed by the Self-Efficacy Scale (SWE), a self-report instrument for measuring general optimistic self-confidence. It consists of 10 items and measures optimistic competence expectancy, i.e., confidence in solving difficult situations with one's own abilities.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period
General substance-related craving
時間枠:From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Substance related craving will be assessed by the MaCS (Mannheim Craving Scale). consists of 12 items and four additional items and is rated on a 5- point Likert scale.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Tobacco dependence
時間枠:From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Tobacco dependence will be assessed by The Fagerström Test for Cigarette Dependence (formerly Fagerström Test for Nicotine Dependence; FTND). It consists of 6 categorically scaled items that assess the number of smoked cigarettes per day (CPD), compulsive use, and dependence intensity.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Primary Affects
時間枠:From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Primary Affects, as proposed by Jaak Panksepp will be assessed by the German Version of the Brief Affective Neuroscience Personality Scales including a LUST Scale (BANPS-GL), a self-report questionnaire.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Metabolome
時間枠:From enrollment to the end of the 6-weeks treatment period.

Metabolome will be ascertained from blood via state-of-the-art NMR (nuclear magnetic resonance).

From enrollment to the end of the 6-weeks treatment period.
Gut microbiome
時間枠:From enrollment to the end of the 6-weeks treatment period.

Gut microbiome will be ascertained via 16s-rRNA sequencing from stool.

From enrollment to the end of the 6-weeks treatment period.
Smoking behaviour
時間枠:From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Participants will be asked regarding their daily smoked cigarettes in the last two weeks (interval scaled). A second single item question will be, if participants have been completely abstinent from tobacco smoking in the last two weeks (dichotome).

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

二次結果の測定

結果測定
メジャーの説明
時間枠
Psychiatric Symptoms
時間枠:From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

For the evaluation of psychopathology, the ICD-10 Symptom Rating (ISR) questionnaire will be utilized. In accordance with the ICD-10, this self-assessment questionnaire, comprising 30 items, is designed to comprehensively assess the status and severity of mental disturbances. Symptoms of the six symptomatic patterns - depressive, anxiety, obsessive-compulsive, eating disorders, somatoform syndrome, and post-traumatic stress disorder - are assessed.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月5日

一次修了 (実際)

2026年9月18日

研究の完了 (実際)

2026年9月18日

試験登録日

最初に提出

2025年1月23日

QC基準を満たした最初の提出物

2025年1月27日

最初の投稿 (実際)

2025年1月31日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年3月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 1155/2024
  • 1155/2024 (その他の識別子:Ethikkommission der Medizinischen Universität Graz)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する